Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group ...

The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to toxicity. The most common treatment-related adverse events were anemia (69%) ...

Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study) The aim of this open-label, ...

To support the design and conduct of clinical research in AKI Core A provides innovative clinical resources to support clinical and translational research in AKI. Firstly, the core provides consulting ...

In clinical trials with sequential patient entry, fixed sample size designs are unjustified on ethical grounds and sequential designs are often impracticable. One solution is a group sequential design ...

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 inhibitor therapy. The rAMBER study highlights Verzenio's potential ...

Dynamic Treatment Regimes (DTRs) represent a paradigm shift in clinical care, moving from a one‐size‐fits‐all model to strategies that adapt treatment over time based on individual patient ...

*Important notice: arXiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or ...

Tachibana provided third quarter 2025 guidance of total company revenue in the range of $12 million to $14 million and pharma test/services revenue in the range of $11 million to $13 million.

BioInvent International AB ($BOVNF) announced an update on their ongoing clinical study. Study Overview: BioInvent International AB, in ...